Since acquiring Bard in a $24 billion deal that closed last December, DeFord has served as BD interventional segment R&D SVP, the Franklin Lakes, N.J.-based company said.
DeFord originally joined Bard as science & tech VP in 2004, and had previously served life sciences managing director for venture capital fund Early Stage Partners and as prez & CEO of Cook Inc, which is now known as Cook Medical. He also currently serves on NuVasive‘s (NSDQ:NUVA) board of directors, BD said.
“John is a recognized leader with more than 25 years of experience in the medical device industry, with expertise overseeing innovative R&D and technology-based initiatives that have made significant effects on saving and improving lives for patients around the world. He will drive organizational culture, capabilities, products and technology-enabled services to further strengthen the BD innovation funnel, while advancing the world of health through new innovations and solutions for our customers and patients,” prez Tom Polen said in a press release.
Kennedy will remain in his present position until a replacement is appointed, the Wayne, Penn.-based company said. After a replacement has been named, Kennedy will stay on to aid in the transition.
The South Jordan, Utah-based company said that it appointed current accounting VP & corporate controller Raul Parra Jr. as its interim CFO. Parra previously held the position of financial reporting director from December 2009 to July 2012.
Before joining Merit, Parra held the position of auditor with Deloitte & Touche from 2003 to 2009.
The Frisco, Texas-based company said it has begun a search for a successor, and that until one is found, Jeremy Friedman will serve as interim CFO.
Friedman is currently responsible for the company’s supply chain, environmental, health, safety and security needs, as well as the divestiture of the company’s advanced spinal & orthopedics product line.
Sleep-disorder focused digital health and medical device company EctoSense said last Friday it named Ciaran McCourt as CEO.
Prior to joining Belgium-based EctoSense, McCourt served as CEO of eDiets and Unilever biometric sensor spin out MiLife. He also served as international biz dev director for BiancaMed, which was acquired by ResMed (NYSE:RMD) in 2014.
“We are very pleased to get someone with Ciaran’s depth of experience on board to drive the company’s high ambitions in delivering scalable and clinically validated diagnostics and services in sleep disorder care globally,” co-founder Bart Van Pee said in a press release
“I am very pleased to take up this role with Ectosense operating at the leading edge of developing innovative respiratory diagnostics, beginning in the domain of sleep apnea with the Nightowl device. The device is a perfectly timed step change in sleep apnea screening and diagnosis given its ease of use and cost of delivery just as patients and providers are seeking ever more convenient devices without sacrificing diagnostic efficacy. I believe the engineering, clinical, and design strengths of Ectosense will ensure its place in the new generation of device companies that will improve access to important disease diagnostics and services,” CEO McCourt said in a prepared statement.